Loading stock data…
PRPO
$30.94+0.04 (+0.13%)
Market ClosedLast close May 1
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Precipio, Inc. in the Healthcare sector is trading at $30.94. The stock is currently near its 52-week high of $32.40, remaining 41.5% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why PRPO maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.94
Potential Upside
5%
Whystock Fair Value$32.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$49.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-83.22%
Volume
Today's trading volume
55,337
Recent News
Precipio, Inc. Q4 2025 Earnings Call Summary
Moby summary of Precipio, Inc.'s Q4 2025 earnings call
Top Stock Reports for AbbVie, Coca-Cola & Chevron
ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
Precipio Inc (PRPO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Precipio Inc (PRPO) achieves positive adjusted EBITDA for the first time, marking a significant financial milestone amidst strategic investments and operational challenges.
The Zacks Analyst Blog Highlights HSBC, American Express, TotalEnergies, Armanino Foods of Distinction and Precipio
HSBC, American Express, TotalEnergies, Armanino Foods, and Precipio stand out in Zacks' latest research highlights.